Forward

Restructure Information

Purdue’s confirmed Plan of Reorganization (“Plan”) was vacated on appeal by the United States District Court for the Southern District of New York. Purdue is appealing the ruling while simultaneously continuing its efforts to forge yet further consensus around a Plan that will deliver billions of dollars to the American people for opioid abatement. The District Court decision does not affect Purdue’s operational stability or its ability to produce its many medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers. The company continues serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives.

READ MORE HERE >

With a dedicated team and a robust pipeline of novel therapy candidates, we work to develop important new medicines that can meaningfully improve the lives of patients around the world.

About Us

Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapeutics.

Learn More

Pipeline

Our robust and diversified pipeline of investigational therapy candidates has been built to address many serious medical conditions.

Learn More

Collaboration

Imbrium is dedicated to collaborating with commercial and academic partners to advance novel therapies that address unmet patient need. We welcome the opportunity to learn about new drug development programs and technologies in the areas of CNS, oncology chemotherapeutics, and non-opioid pain. Please reach us at partnering@54.163.211.251 .